CTRI/2021/03/032293
Not yet recruiting
Phase 3
Randomised, Embedded, Multifactorial, Adaptive, Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) â?? Therapeutic anticoagulation in COVID-19 - REMAP-CAP
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J188- Other pneumonia, unspecified organism
- Sponsor
- Monash University
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Adult patient admitted to an ICU for acute severe CAP within 48 hours of hospital admission with
- •a. symptoms or signs or both that are
- •consistent with lower respiratory tract
- •infection (for example, acute onset of
- •dyspnea, cough, pleuritic chest pain) AND
- •b. Radiological evidence of new onset
- •infiltrate of infective origin (in patients
- •with preexisting radiological changes,
- •evidence of new infiltrate)
- •2\. Up to 48 hours after ICU admission, receiving organ support with one or more of:
Exclusion Criteria
- •1\. Healthcare\-associated pneumonia:
- •a. Prior to this illness, is known to have
- •been an inpatient in any healthcare
- •facility within the last 30 days
- •b. Resident of a nursing home or long\-term
- •care facility.
- •2\. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment.
- •3\. Previous participation in this REMAP within the last 90 days
- •4\. Clinical or laboratory bleeding risk or both that is sufficient to contraindicate therapeutic anticoagulation, including intention to continue or commence dual anti\-platelet therapy
- •5\. Therapeutic anticoagulation is already present due to prior administration of any anticoagulant agent that is known or likely to still be active or a clinical decision has been made to commence therapeutic anticoagulation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Adaptive trial in severe pneumonia Coronavirus COVID-19 (REMAP-CAP-COVID-19)EUCTR2015-002340-14-FRniversity Medical Center Utrecht4,000
Active, not recruiting
Phase 1
Adaptive trial in severe pneumonia (REMAP-CAP)Severe Community Acquired PneumoniaCOVID-19MedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2015-002340-14-NLniversity Medical Center Utrecht20,000
Recruiting
Phase 4
Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)NL-OMON53023niversitair Medisch Centrum Utrecht1,000
Active, not recruiting
Phase 1
Adaptive trial in severe pneumonia (REMAP-CAP)Severe Community Acquired PneumoniaMedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2015-002340-14-FIniversity Medical Center Utrecht4,000
Active, not recruiting
Phase 1
Adaptive trial in severe pneumonia (REMAP-CAP)Severe Community Acquired PneumoniaCOVID-19InfluenzaMedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2015-002340-14-DEniversity Medical Center Utrecht8,000